CADL insider transaction filings
Candel Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-11. Screen CADL transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 18 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 4 filings by 3 insiders — 317,692 shares, $3,550,703 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 220,866 shares @ $11.50 ($2,539,893) by Tak Paul Peter, filed 2026-09-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Tak Paul Peter — Chief Executive Officer, Director | 1 | — | 2 legs · 280,245 sh · $3,160,783 | 2 |
| Barone Francesca — Chief Scientific Officer | 1 | — | 1 leg · 23,447 sh · $235,769 | — |
| Tyagarajan Seshu — Chief Technology Officer | 2 | — | 2 legs · 14,000 sh · $154,151 | — |
| Loggia Nicoletta — Director | 2 | — | — | 2 |
| Manning Paul B — Director | 2 | — | — | 2 |
| PAPA JOSEPH C — Director | 2 | — | — | 2 |
| Benz Edward J. JR — Director | 1 | — | — | 1 |
| Gaeta Renee — Director | 1 | — | — | 1 |
| Martell Christopher — Director | 1 | — | — | 1 |
| Nabel Gary J. — Director | 1 | — | — | 1 |
+4 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Candel Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Tak Paul Peter — Chief Executive Officer, Director | Option exercise (M): 125,000 @ $1.55 · Sale (S): 220,866 @ $11.50 · Sale (S): 59,379 @ $10.46 · Option exercise (M): 125,000 (derivative) @ $0 | EDGAR |
| 2026-09-10 | 4 | Zimmermann Martine — Director | Grant/award (A): 64,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Tyagarajan Seshu — Chief Technology Officer | Sale (S): 7,000 @ $12 | EDGAR |
| 2026-07-08 | 4 | Sims Mark E. — Chief Commercial Officer | Grant/award (A): 285,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Loggia Nicoletta — Director | Grant/award (A): 381 (derivative) @ $8.64 | EDGAR |
| 2026-07-01 | 4 | Tyagarajan Seshu — Chief Technology Officer | Sale (S): 7,000 @ $10.02 | EDGAR |
| 2026-07-01 | 4 | Barone Francesca — Chief Scientific Officer | Sale (S): 23,447 @ $10.06 | EDGAR |
| 2026-07-01 | 4 | Manning Paul B — Director | Grant/award (A): 2,199 (derivative) @ $8.64 | EDGAR |
| 2026-07-01 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 1,331 (derivative) @ $8.64 | EDGAR |
| 2026-06-24 | 4 | Radhakrishnan Maha — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Loggia Nicoletta — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Martell Christopher — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Nabel Gary J. — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Nguyen Diem — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Gaeta Renee — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Benz Edward J. JR — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Manning Paul B — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Loggia Nicoletta — Director | Grant/award (A): 779 (derivative) @ $4.11 | EDGAR |
| 2026-04-02 | 4 | Manning Paul B — Director | Grant/award (A): 4,618 (derivative) @ $4.11 | EDGAR |
| 2026-04-02 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 2,795 (derivative) @ $4.11 | EDGAR |
| 2026-02-26 | 4 | Manning Paul B — Director | Purchase (P): 550,458 @ $5.45 | EDGAR |
| 2026-01-28 | 4 | Tyagarajan Seshu — Chief Technology Officer | Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Schoch Charles — Chief Financial Officer | Grant/award (A): 232,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Tak Paul Peter — Chief Executive Officer, Director | Grant/award (A): 629,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Barone Francesca — Chief Scientific Officer | Grant/award (A): 232,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Nichols William Garrett — Chief Medical Officer | Grant/award (A): 136,500 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Nichols William Garrett — Chief Medical Officer | Option exercise (M): 937 @ $1.29 · Sale (S): 937 @ $6.98 · Option exercise (M): 937 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Nichols William Garrett — Chief Medical Officer | Option exercise (M): 781 @ $1.29 · Sale (S): 781 @ $5.04 · Option exercise (M): 781 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Tyagarajan Seshu — Chief Technology Officer | Grant/award (A): 5,353 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Tak Paul Peter — Chief Executive Officer, Director | Grant/award (A): 42,826 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Martell Christopher — Director | Grant/award (A): 111,349 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Loggia Nicoletta — Director | Grant/award (A): 2,141 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Barone Francesca — Chief Scientific Officer | Grant/award (A): 4,282 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Schoch Charles — Chief Financial Officer | Grant/award (A): 5,353 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Nabel Gary J. — Director | Grant/award (A): 5,353 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | Manning Paul B — Director | Grant/award (A): 1,070,663 @ $4.67 | EDGAR |
| 2025-06-26 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 64,239 @ $4.67 | EDGAR |
| 2025-06-24 | 4 | Schoch Charles — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Loggia Nicoletta — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Martell Christopher — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Nabel Gary J. — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Nguyen Diem — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Gaeta Renee — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Benz Edward J. JR — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Manning Paul B — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Radhakrishnan Maha — Director | Grant/award (A): 28,480 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4/A | Tyagarajan Seshu — Chief Technology Officer | Option exercise (M): 20,000 @ $1.29 · Sale (S): 31,278 @ $8.82 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | Nichols William Garrett — Chief Medical Officer | Option exercise (M): 4,584 @ $3.75 · Option exercise (M): 13,905 @ $1.29 · Sale (S): 45,316 @ $8.76 · Option exercise (M): 4,584 (derivative) @ $0 · Option exercise (M): 13,905 (derivative) @ $0 | EDGAR |
Recent 8-K events — Candel Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CADL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →